Physician profile
Michael Correa
NPI 1083765531
$22,688.78
in general payments reported to CMS, 2019-2025
61 companies · $3,884 in 2025
The $3,884 reported for 2025 was more than what 97% of Internal Medicine providers received nationally (typical 2025 total: $156).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $3,266 · 2020: $2,979 · 2021: $3,722 · 2022: $3,012 · 2023: $2,837 · 2024: $2,988 · 2025: $3,884.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $9,602 · Education: $108.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $9,601.53 |
| Education | $108.21 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $3,158.90 | 2019-2025 | Vraylar, Qulipta, Ubrelvy |
| Astrazeneca Pharmaceuticals LP | $2,584.89 | 2019-2025 | Breztri, Farxiga, Airsupra |
| Boehringer Ingelheim Pharmaceuticals, INC. | $2,216.77 | 2019-2025 | Jardiance, Ofev |
| Novo Nordisk INC | $1,445.29 | 2019-2025 | Ozempic, Wegovy, Rybelsus |
| Glaxosmithkline, LLC. | $1,238.90 | 2019-2025 | Trelegy Ellipta, Arexvy, Shingrix |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $1,103.06 | 2019-2025 | Xifaxan, Trulance |
| Gilead Sciences, INC. | $817.29 | 2019-2024 | Descovy |
| Lilly USA, LLC | $807.87 | 2019-2025 | Zepbound, Mounjaro, Jardiance |
| Novartis Pharmaceuticals Corporation | $754.35 | 2019-2025 | |
| Bayer Healthcare Pharmaceuticals INC. | $748.34 | 2021-2025 | |
| Astellas Pharma US INC | $685.00 | 2019-2025 | Veozah, Myrbetriq |
| Amgen INC. | $654.54 | 2019-2025 | Otezla, Repatha, Krystexxa |
| Pfizer INC. | $618.93 | 2019-2025 | |
| Amarin Pharma, INC. | $564.87 | 2019-2022 | |
| Allergan, INC. | $530.99 | 2019-2020 |
Show all 61 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Michael Correa listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.